Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SARS-CoV-2 replicates in respiratory ex vivo organ cultures of domestic ruminant species

Giovanni Di Teodoro, Fabrizia Valleriani, Ilaria Puglia, Federica Monaco, Chiara Di Pancrazio, Mirella Luciani, Ivanka Krasteva, Antonio Petrini, Maurilia Marcacci, Nicola D’Alterio, Valentina Curini, Mariangela Iorio, Giacomo Migliorati, Marco Di Domenico, Daniela Morelli, Paolo Calisti, Giovanni Savini, Nicola Decaro, Edward C. Holmes, Alessio Lorusso

a Istituto Zooprofilattico Sperimentale dell’Abruzzo e Molise, Teramo, Italy
b Department of Veterinary Medicine, University of Bari, Valenzano, Bari, Italy
c Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Life and Environmental Sciences and School of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia

ARTICLE INFO

Keywords:
SARS-CoV-2
Respiratory ex vivo organ cultures
Cattle
Sheep
Pigs
ACE2
Tropism
Replication
D614G

ABSTRACT

There is strong evidence that severe acute respiratory syndrome 2 virus (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic, originated from an animal reservoir. However, the exact mechanisms of emergence, the host species involved, and the risk to domestic and agricultural animals are largely unknown. Some domestic animal species, including cats, ferrets, and minks, have been demonstrated to be susceptible to SARS-CoV-2 infection, while others, such as pigs and chickens, are not. Importantly, the susceptibility of ruminants to SARS-CoV-2 is unknown, even though they often live in close proximity to humans. We investigated the replication and tissue tropism of two different SARS-CoV-2 isolates in the respiratory tract of three farm animal species - cattle, sheep, and pigs - using respiratory ex vivo organ cultures (EVOCs). We demonstrate that the respiratory tissues of cattle and sheep, but not of pigs, sustain viral replication in vitro of both isolates and that SARS-CoV-2 is associated to ACE2-expressing cells of the respiratory tract of both ruminant species. Intriguingly, a SARS-CoV-2 isolate containing an amino acid substitution at site 614 of the spike protein (mutation D614G) replicated at higher magnitude in ex vivo tissues of both ruminant species, supporting previous results obtained using human cells. These results suggest that additional in vivo experiments involving several ruminant species are warranted to determine their potential role in the epidemiology of this virus.

1. Introduction

Coronavirus disease 2019 (COVID-19) was recognized as a public health emergency of international concern on January 30, 2020 and acknowledged as a pandemic on March 11, 2020 (Zhou et al., 2020). COVID-19 is caused by a novel human coronavirus (CoV) now referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), species SARS-related coronavirus, subgenus Sarbecovirus, genus Betacoronavirus, subfamily Orthocoronavirinae, family Coronaviridae (Decaro and Lorusso, 2020; Gorbalenya et al., 2020). COVID-19 was first reported in December 2019 in the city of Wuhan, Hubei Province, China, in humans largely connected to the Huanan seafood wholesale market and where different species of farm and wild animals are commonly sold (Decaro and Lorusso, 2020; 2020a), although the role of the market in virus emergence is uncertain. COVID-19 is mainly a respiratory infection, with the most common symptoms comprising fever, dry cough, and shortness of breath. About 20% of infected patients may develop severe disease, and a small percentage (5%) may become critically ill. Patients with severe COVID-19 disease usually develop pneumonia or acute respiratory distress syndrome (ARDS), a condition that may require mechanical ventilation and intensive care unit treatment (Yang et al., 2020). ARDS is often fatal (Matthay et al., 2019).

The recognition of and interaction with host cellular receptors are critical initial steps in the virus life cycle and play a key role in shaping
host range, tissue tropism and viral pathogenesis. The numerous func-
tions of viral receptors enable the virus to target the correct tissues for
infection and breach cellular barriers. Interactions with viral receptors
are usually mediated by specific viral attachment proteins expressed on
the surface of the virion. SARS-CoV-2, like the earlier SARS-CoV that
emerged in 2002/2003, uses the receptor binding domain (RBD) of the
viral S1 portion of the spike (S) protein to bind to the angiotensin-
converting enzyme 2 (ACE2) receptor that is widespread in several tis-
ues of mammals (Zhou et al., 2020; Hoffmann et al., 2020; Wang et al.,
2020; Damas et al., 2020). It is reasonable to think that mutations in this
viral protein could potentially have dramatic effects on viral patho-
genesis, replication, and tropism. Analyses of over 28,000 S gene se-
quences in May 2020 revealed a D614G (23403A > G) amino acid
substitution that was rare before March but increased in frequency as the
pandemic spread, reaching over 74% of all published sequences by June
2020 (Yurkovetskiy et al., 2020). Notably, it has been proposed that
D614G increases infectivity in cell assays in vitro and is also proposed
to enhance viral transmissibility in nature (Plante et al., 2020; Korber
et al., 2020). The D614G substitution is accompanied by a set of muta-
tions including 241C > T in the leader sequence, 3037C > T, and
14408C > T. While 3037C > T causes a synonymous mutation in nsp3
(F105 F), 14408C > T is responsible for a substitution in the RNA pri-
mase (nsp 12, P323L) (Lorusso et al., 2020a). The latter finding may in part explain the absence of
SARS-CoV-2/IZSAM/46419 sequence differs from that of
SARS-CoV-2/INMI1-Isolate/2020/Italy for 241C > T, 3037C > T,
14408C > T and 23403A > G. This latter leads to the non-synonymous
mutation in the S protein encoding gene, D614G. Therefore,
SARS-CoV-2/INMI1-Isolate/2020/Italy is indicated as D614 throughout
the manuscript, while SARS-CoV-2/IZSAM/46419 as D614G.

2.2. Viruses

Four virus isolates at low cell passage were used to infect the respi-
rotary EVOCs: (i) SARS-CoV-2/INMI1-Isolate/2020/Italy (kindly
donated by the Istituto Nazionale Malattie Infettive Lazzaro Spallanzani,
Rome, Italy) and nucleotide sequence of which is available on the
GISAID website (accession BetaCoV/Italy/INMI-isl-2020: EPI_-
ISL_410545); (ii) SARS-CoV-2/IZSAM/46419 (GISAID, hCoV-19/Italy-
ABR-ISZGC-TE46419/2020; (iii) bovine para-influenza virus 3 (BPIV-3,
species Bovine respirivirus 3, genus Respirivirus, family Paramyxoviridae,
T1 strain, Weybridge, UK) and (iii) suid herpes virus 1 (SuHV-1, species
Suid alphaherpesvirus 1, genus Varicellovirus, subfamily Alphaherpesvir-
iniae, family Herpesviridae, strain ADV32751/Italy2014 (Pizzurro et al.,
2016)). Experiments with SARS-CoV-2 were performed in BSL-3 con-
ditions as described previously (b). Both SARS-CoV-2 isolates have been
isolated on VERO E6 cells (monkey kidney epithelial cells).
SARS-CoV-2/IZSAM/46419 sequence differs from that of
SARS-CoV-2/INMI1-Isolate/2020/Italy for 241C > T, 3037C > T,
14408C > T and 23403A > G. This latter leads to the non-synonymous
mutation in the S protein encoding gene, D614G. Therefore,
SARS-CoV-2/INMI1-Isolate/2020/Italy is indicated as D614 throughout
the manuscript, while SARS-CoV-2/IZSAM/46419 as D614G.

2.3. Screening of serum and tissue samples

Serum samples were collected from animals before tissue collection
and tested for the presence of neutralizing antibodies against SuHV-1,
BPIV-3, bovine coronavirus (BCoV, species Betacoronavirus 1, subgenus
Embecovirus, genus Betacoronavirus, subfamily Orthocoronavirinae, fam-
ily Coronaviridae), strain 438/06, (Decaro et al., 2008), and SARS-CoV-2
by serum neutralization (IZSAM). Swab (respiratory and rectal) samples
were also collected and purified nucleic acids extracted from them
(using the MagMAX viral Pathogen II Nucleic Acid isolation kit, Ther-
mofisher) and from a portion of collected tissues were tested for the
presence of SARS-CoV-2 (TaqManTM 2019-nCoV Assay Kit v2, Ther-
mofisher), SuHV-1 (Adiavet PRV Real Time, Adiagen), swine coronavi-
uses (VetMAX™ PEDV/TEGV/SDCoV Kit (Applied Biosystems), BCoV
(LSI VetMAX™ Ruminant Rotavirus & Coronavirus Kit (Applied Bio-
systems)) and BPIV-3 virus (LSI VetMAX™ Triplex BRSV & PI3 Kit (Applied Biosystems)).

2.4. Culture and infection of respiratory EVOCs

Tracheal and lung EVOCs culture and viability were assessed as
described previously (Di Teodoro et al., 2018, 2019). Briefly, at the
slaughterhouse, the cranial portion of trachea and the right lung were
immediately collected after the stunning and bleeding of the animals.
Samples were stored at 4 °C and delivered to the laboratory.

To obtain tracheal EVOCs, the tracheal mucosa was stripped from the
cartilage rings, cut in squares of about 25 mm² and washed with warm
phosphate buffered saline (pH 7.4, PBS). Tissue samples were then
 transferred into 24-well plates. To obtain lung EVOCs, the main bron-
chus was catheterized, and the lung parenchyma embedded with 1% low
gelling temperature agarose (type VII-A agarose, Sigma-Aldrich) pre-
warmed at 37 °C. The lung lobe was then cooled to 4 °C and delivered to the
laboratory.

To obtain tracheal EVOCs, the tracheal mucosa was stripped from the
cartilage rings, cut in squares of about 25 mm² and washed with warm
phosphate buffered saline (pH 7.4, PBS). Tissue samples were then
 transferred into 24-well plates. To obtain lung EVOCs, the main bron-
chus was catheterized, and the lung parenchyma embedded with 1% low
gelling temperature agarose (type VII-A agarose, Sigma-Aldrich) pre-
warmed at 37 °C. The lung lobe was then cooled to 4 °C for 20 min and
cut into 1 mm thick slices. Lung tissue samples of 25 mm² were then
 transferred into 24-well plates. All EVOCs were cultured in an air–liquid
interface system, slightly immersed in 1 mL of tissue culture medium
(DMEM addicted with 1% of glutamine, 1% of Penicillin/Strepto-
mycin/Amphotericin B Solution, Thermo-Fisher). EVOCs were incu-
ated at 37 °C with 5% CO₂ for up to 72 h.

Tracheal and lung EVOCs were infected with 10³ TCID₅₀/mL of both
SARS-CoV-2 isolates, BPIV-3, and SuHV-1 virus by submerging the
explanted tissues in 1 mL of each virus dilution. After 1 h at 37 °C in 5% CO₂, EVOCs were washed three times with warm PBS to remove non-
attached virus particles and cultured in 1 mL of fresh tissue culture

2. Materials and methods

2.1. Animals

Three 12-month old pigs, three 18-month old cattle and three 10-
month-old sheep were used to obtain respiratory EVOCs. Sampling
was performed in accordance with internal guidelines of the slaughter-
house (Centro Carni Val Tordino, Mosciano S. Angelo, Teramo-Italy) where
the animals were officially slaughtered. All animals originated
from herds located in the Abruzzi region of central Italy. All procedures,
including handling and processing of tissues, were performed according
to the internal guidelines of the Istituto Zooprofilattico Sperimentale
dell’Abruzzo e Molise (IZSAM).
media at 37 °C in 5% CO₂ up to 72 h. Virus-free culture medium was used for mock-infected EVOCs. To study viral replication, 300 μl of supernatant was collected at 1, 24, 48 and 72 h post infection (hpi). The supernatants were titrated by TCID₅₀ assay on VERO E6 cells. In addition, to determine the number of viral genome copies over time, viral RNA purified from EVOCs supernatants was tested by TaqMan™ 2019-nCoV Assay Kit v2. The absolute quantification of viral RNA was determined by a standard curve method using an RNA standard (Twist Synthetic SARS-CoV-2 RNA Controls, Twist Bioscience, San Francisco-CA, USA). As the adopted molecular assay detects three genes of SARS-CoV-2 genome namely ORF1ab, S and N protein encoding genes, for practical reasons, quantification has been performed only for the N protein encoding gene.

2.5. Immunohistochemistry for angiotensin converting enzyme 2 (ACE2)

To study the ACE2 immunohistochemical expression, trachea and lung specimens of the same animals included in the study were immediately fixed in 10 % neutral buffered formalin at the slaughterhouse and processed for histology. Three μm-thick sections were dewaxed, rehydrated, and incubated overnight at 4 °C with a rabbit anti-ACE2 polyclonal antibody (Abcam; ab15348). Immunoreactions were visualized using a biotin-streptavidin amplification method and 3-3′-diaminobenzidine as chromogen (Dako REAL™ detection system). According to the manufacturer, this polyclonal antibody binds to human ACE2, although it is also predicted to bind to the ACE2 of cat, dog, monkey, and orangutan.

2.6. Western blotting for detection of angiotensin converting enzyme 2 (ACE2)

The specificity of the anti-ACE2 antibody used in this study and its capability to detect ACE2 of different animal species was assessed by western blotting. For this purpose, bovine, ovine and swine kidney tissues (Hamming et al., 2004) from the same animals included in this study, were lysed with cellLyticMT reagent (Sigma) with a 1:20 ratio. Caco-2 cell line was used as positive control as reported in the manufacturer instructions of the adopted antibody. Lysates/proteins at 15 μg per lane were separated by NuPAGE 4–12 % Bis-Tris gel (Novex, Life Technologies) at 200 V and then transferred onto iBlot2 NC stacks (Life Technologies). Membranes were blocked with PBS containing 0.05 % Tween 20 (PBST) and 5% skimmed milk for 2 h at room temperature. Membranes were incubated overnight at room temperature with rabbit anti ACE2 polyclonal antibody (Abcam; ab15348) at a concentration of 2 μg/mL diluted in PBST containing 2.5 % skimmed milk. After washing with PBST, membranes were incubated for 1 h at room temperature with goat anti-rabbit IgG-HRP (Bio-Rad) diluted...
1:3000 in PBST containing 2.5 % skimmed milk. Antigen-antibody reactions were visualized by adding chemiluminescent substrates (GE Healthcare). Images were acquired using the ChemiDoc MP (Bio-Rad) and the Image Lab Software, version 4.0.1 (Bio-Rad).

2.7. Immunohistochemistry, double labelling indirect immunofluorescence and confocal microscopy

To study the cellular tropism of both SARS-CoV-2 isolates, three replicates of virus- and mock-infected respiratory EVOCs were fixed in 10 % neutral buffered formalin at 1, 24, 48 and 72 hpi and processed for immunohistochemistry (IHC). For IHC, three μm-thick sections of EVOCs were dried at 37 °C, dewaxed and rehydrated by standard procedures. Antigen retrieval was performed by autoclaving at 121 °C for 10 min in 0.01 M citrate buffer, pH 6. Sections were incubated overnight at 4 °C with a primary rabbit anti-SARS-nucleoprotein antibody (NovusBio; NB100-56576). Immunoreactions were visualized using a biotin-streptavidin amplification method and 3,3′-diaminobenzidine as chromogen (Dako REAL™ detection system).

For DLIIF and CM investigations three μm-thick tissue sections of SARS-CoV-2-infected bovine and ovine EVOCs were incubated overnight at 4 °C with a monoclonal anti-SARS-CoV-2 spike antibody (clone 1A9, GeneTex; GTX632604) and, simultaneously, with a rabbit anti-ACE2 polyclonal antibody (Abcam; ab15348) as primary antibodies. Immune reactions were visualized using anti-mouse and anti-rabbit IgG biotinylated as secondary antibodies (Vector Laboratories, Inc.), respectively, followed by incubation with streptavidin conjugate Alexa Fluor™ 546 (Invitrogen) and Fluorescein Avidin D FITC (Vector Laboratories, Inc.) as fluorochromes. Sections were mounted using an anti-fade medium with 4′,6-diamidino-2-phenylindole (DAPI, Vector Laboratories, Inc.), and imaged using a Leica TCS SP5 II confocal laser microscope. Suitable positive and negative controls were included in each IHC and DLIIF run.

2.8. Sequence analysis

RNAs purified from the supernatants collected at 72 hpi from EVOCs of both ruminant species infected with the two SARS-CoV-2 isolates were used for next generation sequencing (NGS). The two isolate stocks used for infection were also sequenced. RNA samples were amplified by ARTIC amplicon sequencing protocol (Itokawa et al., 2020) and then library preparation was carried out by using Illumina® DNA Prep, (M) Tagmentation (24 Samples) (Illumina Inc., San Diego, CA USA). Deep sequencing was performed on the MiSeq (Illumina Inc., San Diego, CA) by the MiniSeq Mid Output Kit (300-cycles) and standard 150 bp paired-end reads. Quality control was performed using FASTQC quality control software v0.11.9. Analysis was performed by means of the SeqMan NGen of the Lasergene Genomics tool suite (DNASTAR, Inc.,

Fig. 2. Quantification of SARS-CoV-2 RNA in bovine, ovine and swine respiratory EVOCs. Number of RNA copies of SARS-CoV-2 in EVOC supernatants infected with a dose of 10^3 TCID₅₀/mL of the D614 and D614G strains increased significantly in bovine and ovine EVOCs from 1 to 72 hpi (p < 0.05). Quantification of RNA copies in EVOC supernatants revealed more evident differences between D614 and D614G. Specifically, in bovine EVOCs, differences were significant at 72 hpi in both tissues (p < 0.001), while in ovine EVOCs, differences were significant at 48 (p < 0.05) and 72 hpi (p < 0.01) in trachea, 24 and 48 hpi in lung (p < 0.01). In swine EVOCs, SARS-CoV-2 genome copies did not change over time. Values represent the mean of three replicates of three independent experiments. Bars indicate standard deviation (SD). * (p < 0.05), ** (p < 0.01), *** (p < 0.001).
2.9. Statistical analysis

Sample sizes were calculated using the G*Power software (Heinrich-Heine Universität Düsseldorf, Germany). All statistical analyses were performed using GraphPad Prism software, version 8.4.3 (GraphPad Software Inc., San Diego, USA). Results were expressed as means ± standard deviation (SD) derived from three replicates of three independent experiments (one animal for each experiment). Multiple Student t-test were performed to compare sets of data. Differences were considered statistically significant when $p$ value was ≤ 0.05.

3. Results

3.1. Animals tested negative for the viral pathogens studied

All animals included in the study tested virologically negative for BPIV-3 virus, SuHV-1, BCoV, swine coronaviruses, and SARS-CoV-2 prior to the start of the EVOC experiments. In addition, serum samples tested negative for BPIV-3, SuHV-1, BCoV, and SARS-CoV-2 by serum neutralization.

3.2. BPIV-3 and SuHV-1 replication confirms the viability of respiratory EVOCs

The viability of explanted respiratory tissues was confirmed by the marked replication of common respiratory pathogens - BPIV-3 and SuHV-1 – that comprised positive control respiratory viruses. BPIV-3 replicated at the approximately the same magnitude and exhibited the same temporal trend in both ruminant respiratory EVOCs, with titers slightly higher in lung EVOCs compared to those from the trachea. Virus titers of BPIV-3 and SuHV-1 at 24-, 48- and 72- hpi were significantly higher (indicating viral growth and tissue viability) in all tissues with respect to those at 1hpi ($p < 0.05$, Supplementary Material).

3.3. SARS-CoV-2 does not replicate in swine EVOCs

Although the viability of swine EVOCs was confirmed by the growth of SuHV-1, both SARS-CoV-2 isolates failed to replicate in lung and tracheal EVOCs from pigs as statistically significant differences were not observed between either infectious viral titers on cells or RNA copies at 1 hpi and 72 hpi ($p > 0.05$) (Figs. 1,2). Differences between the two
SARS-CoV-2 isolates were observed only at 24 hpi in tracheal EVOCs as D614G virus showed a slight, but statistically significant, higher number of RNA copies.

3.4. SARS-CoV-2 with D614G exhibits greater replication

SARS-CoV-2 isolates showed marked replication in bovine and ovine EVOCs as demonstrated by the increase of viral titers (Fig. 1) and RNA copies (Fig. 2) over time. More in details, in bovine and ovine respiratory tissues, titers of both viruses were significantly higher at 72 hpi when compared to the earliest time point (p < 0.05). As for bovine tissues, viral titers of both SARS-CoV-2 isolates were higher in lung than trachea (up to 2 Log_{10}), whereas titers of both viruses were of comparable levels in ovine tissues. An analysis of viral titers revealed that D614G replicated in bovine tissues at higher magnitude than D614 at 48 hpi (p < 0.05) in tracheal EVOCs; at 48 hpi (p < 0.01) and 72 hpi (p < 0.05) in lung EVOCs. In ovine tissues, both viruses replicated at comparable levels. Quantification of RNA copies in EVOCs supernatants revealed more apparent differences between D614 and D614G. In particular, in bovine EVOCs, differences were significant at 72 hpi in both tissues (p < 0.001), while in ovine EVOCs differences were significant at 48 (p < 0.05) and 72 (p < 0.01) hpi in trachea, 24 (p < 0.01) and 48 (p < 0.01) hpi in lung (Fig. 2).

3.4.1. Immunoreactivity for ACE2 is mainly present in bovine and ovine respiratory epithelial cells

The polyclonal antibody analysis revealed the presence of ACE2 expressing cells in the tracheal (Fig. 3A, C) and bronchiolar (Fig. 3B, D) epithelia of sheep and cattle. Notably, in our experimental settings, immunoreactivity was not observed in both porcine tissues (Fig. 4E, F).

3.4.2. The anti-ACE2 polyclonal antibody recognizes bovine, ovine and swine ACE2

Western blotting analysis revealed high intensity and specific bands of approximately 90–100 kDa (predicted molecular weight of ACE2 is 97 kDa) in bovine, ovine, and porcine kidney lysates. The predicted band was also observed in the Caco-2 cell line lysate (Fig. 4). This indicates that the adopted antibody is able to bind to porcine ACE2.

3.4.3. SARS-CoV-2 has tropism for bovine and ovine respiratory ACE2-expressing cells

SARS-CoV-2 antigens were visualized by IHC in cells of the tracheal epithelia of both ruminant species (Fig. 5A, E). In lung parenchyma, SARS-CoV-2 was detected in the morphologically spindled epithelial type I pneumocytes and in bronchiolar cells (Fig. 5B, F). In addition, immunoreactivity for SARS–COV-2 was observed in alveolar macrophages of bovine lung (Fig. 5B). Immunoreactivity was not detected in swine respiratory and in mock infected EVOCs (Fig. 5I, J, K, L, C, D, G, H). Double labelling indirect immunofluorescence (DILIIF) and confocal microscopy (CM) analyses performed in bovine and ovine SARS-CoV-2 infected EVOCs, revealed viral S protein in association with tracheal and pulmonary ACE2 positive cells (Fig. 6) of both species. CM and DILIIF analyses were not performed in porcine tissues because of the absence of viral replication and SARS-CoV-2/ACE2 immunoreaction in these EVOCs. No immunoreactivity for viral S protein was observed in mock infected EVOCs (data not shown). No differences were observed in terms of tropism between the two SARS-CoV-2 isolates.

3.5. Mutations in the consensus sequences were not observed

In this round of experiments, consensus sequences obtained from viruses collected from EVOCs were identical to those obtained from viral inocula.

4. Discussion

EVOCs of the respiratory tract from different animal species have been developed to study the cellular tropism and infectivity of respiratory viral pathogens (Pena et al., 2012; Di Teodoro et al., 2019). In this setting, the three-dimensional structure and cell diversity of the respiratory mucosa and lung parenchyma are preserved along with other important physiological features, including the normal expression levels of cell receptors, effective mucus production and ciliary activity. EVOCs have been used also to characterize innate immune responses, host range, and tropism of different viruses, including SARS-CoV-2 (Nicholls et al., 2007; Niesalla et al., 2009; Chan et al., 2013; Gonzalez et al., 2014; Chan et al., 2016; Hui et al., 2020; Chu et al., 2020). Herein, we demonstrated that bovine and ovine respiratory tissues were permissive to SARS-CoV-2 infection as viral infectious titers and viral genome copies significantly increased over time. This is suggestive of viral replication, although clearly needs to be confirmed with additional studies. Importantly, we demonstrated that a SARS-CoV-2 isolate containing the D614G mutation in the S protein possessed enhanced replicative capabilities compared to earlier strains, represented here by a SARS-CoV-2 strain collected from a Chinese tourist who visited Rome, Italy, in January 2020. Because the SARS-CoV-2/IZSAM/46419 isolate with D614G is accompanied by three additional mutations in the viral genome, it can be reasonably argued that the enhanced replicative capabilities observed here are not necessarily associated with D614G. However, the effects of D614G on viral replication have recently been demonstrated in both human cells and hamsters (Plante et al., 2020). We therefore speculate that D614G played a role by enhancing the replicative capabilities of SARS-CoV-2/IZSAM/46419 in the experiments we performed. Nevertheless, additional studies are required to confirm the
higher fitness and infectivity of D614G viruses in animal tissues.

Although pig tissues were viable as demonstrated by the viral burden of SuHV-1, both SARS-CoV-2 isolates did not show replication, confirming results previously obtained following in vivo experimental infection (Schlottau et al., 2020; Shi et al., 2020; Meekins et al., 2020). As demonstrated by western blotting analysis, the polyclonal antibody was able to recognize and bind to porcine ACE2 from kidney. Hence, the absence of viral replication in respiratory tissues is likely explained by the absence of ACE2 moieties in porcine respiratory tissues as suggested by the absence of immunohistochemical reactivity for this receptor. In turn, ACE2 immunoreactivity was present in respiratory tissues of cattle and sheep. Finally, SARS-CoV-2 was associated with ACE2-expressing cells of lung and trachea of both ruminant species, suggesting the affinity of this virus for the ACE2 of these animals as previously proposed (Zhai et al., 2020).

SARS-CoV-2 is the most recent example of an emerging zoonotic virus that has converted its ‘pandemic potential’ into reality (Gollakker and Capua, 2020), and that likely has an origin in another mammalian species (Andersen et al., 2020). Although SARS-CoV-2 is able to infect several animal species in close contact with humans, such as minks (Oreshkova et al., 2020), the potential of SARS-CoV-2 to become established in other animal species is unclear.

4.1. Conclusions

Our results strongly suggest that in vivo experiments involving ruminant species are warranted to help determine the clinical outcome of infection in these species and their potential role as host animals. Importantly, however, EVOCs experiments are only suggestive that these animal species may be susceptible to infection, and more confirmatory work is clearly warranted. More generally, our study highlights the potential for diverse animal species to play a role in the epidemiology of SARS-CoV-2 as well as the need for a One Health approach to tackle this major global problem (2020b).
5. Funding

IZSAM funding was provided by the Italian Ministry of Health (Ricerca Corrente 2015 “Strategie innovative per la riduzione della sperimenterazione animale: cure di spianti di tessuti e virus-istochimica”, recipient Giovanni Savini and Ricerca Corrente 2020 “PartCo: epidemiologia e patogenesi dei coronavirus umani ed animali”, recipient Alessio Lorusso). ECH is supported by an Australian Research Council (ARC) Australian Laureate Fellowship (FL170100022). Mention of trade names or commercial products in this article is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the IZSAM.

Declaration of Competing Interest

The authors report no declarations of interest.

Acknowledgement

We gratefully thank Dr Paola Di Giuseppe (IZSAM) for support in formatting figures.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.vetmic.2020.108933.

References

Andersen, K.G., Rambaut, A., Lipkin, W.I., Holmes, E.C., Garry, R.F., 2020. The proximal origin of SARS-CoV-2. Science 368, 313–319. doi:https://doi.org/10.1126/science.abc8807.

Gollan, K.R., Marshall, J.F., Moss, B., Robb, D., McCauley, J.W., Perez, D.R., Parrish, C.R., Murcia, P.R., 2014. Infection and pathogenesis of canine, equine, and human influenza viruses in canine tracheas. J. Virol. 88, 9208–9219. doi:https://doi.org/10.1128/JVI.02034-14.

Gorbalenya, A.E., Baker, S.C., Baric, R.S., de Groot, R.J., Drosten, C., Gulyaeva, A.A., Haagmans, B.L., Lauwer, C., Leontovich, A.M., Neuman, B.W., Perlman, D., Perlman, S., Poon, L.L.M., Samborsky, D.V., Sidorenko, I.A., Solja, I., Zieheb, J., 2020. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544. doi:https://doi.org/10.1038/s41564-020-0695-z.

Harmeling, I., Timens, W., Bulbuc, M.L.C., Lely, A.T., Navis, G.J., Van Goor, H., 2004. Contribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. doi:https://doi.org/10.1002/jpath.1570.

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T.S., Herrler, G., Wu, N.H., Nitsche, A., Müller, M., Drosten, C., Pöhlmann, S., 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181. doi:https://doi.org/10.1016/j.cell.2020.02.052.

Hui, K.P.Y., Cheung, M.C., Pereira, R.A.P.M., Ng, K.C., Bui, C.H.T., Ho, J.C.W., Ng, M.M.T., Koop, D.J.T., Shih, K.C., Tsao, S.W., Poon, L.L.M., Peiris, M., Nicholls, J.M., Chan, M.C.W., 2020. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex vivo and in vitro cultures. Lancet Respir. Med. 8, 687–695. doi:https://doi.org/10.1016/S2213-2600(20)30193-4.

Iokawa, K., Sekizuka, T., Hashino, T., Tanaka, R., Kuroda, M., 2020. Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplexing PCR. PLOS ONE. doi:https://doi.org/10.1371/journal.pone.0248943.

Korber, B., Fischer, W.M., Gnanakaran, S., Yoon, H., Thelher, J., Abalterer, W., Hengartner, N., Giorgi, E.E., Bhattacharya, T., Foley, B., Hastie, K.M., Parker, M.D., Partridge, D.G., Evans, C.M., Freeman, T.M., de Silva, T.L., 2020. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G increases infectivity of the COVID-19 Virus. Cell 82–872.

Lorusso, A., Calistri, P., Petroni, A., Savini, G., Decaro, N., 2020a. Novel coronavirus (SARS-CoV-2): an epidemiological perspective. Vet. Ital. 56, 5–10. doi:https://doi.org/10.12834/VetIt.21311599.1.

Lorusso, A., Calistri, P., Mercante, M.T., Fornito, O., Marazzi, M., Gollakner, R., Capua, I., 2020. Could Minkelis spur COVID-19 into a zoopanzootic? Vet. Ital. doi:https://doi.org/10.12834/VetIt.2375.13627.1.

Matthay, M.A., Zemans, R.L., Zimmerman, G.A., Bhat, Y.M., Beiler, J.R., Mercat, A., Herridge, M., Randolph, A.G., Caffee, C.S., 2019. Acute respiratory distress syndrome. Nat. Rev. Di. Prim. doi:https://doi.org/10.1038/s41571-019-0069-0.

Meekins, D.A., Morozov, I., Trujillo, J.D., Gaudreault, N.N., Bold, D., Carassiti, M., Camma, C., Rinaldi, A., Mangone, I., Di Pasquale, A., Jommarini, M., Mattucci, M., Fazzi, P., Tarquini, P., Mariani, K., Grimaldi, M., Migliorati, G., Savini, G., Boronelli, S., D’Aliterio, N., Capra, L., 2020. Clinical and Pathological Findings in SARS-CoV-2 Disease Outbreaks in Farmed Mink (Neovison vison). Vet. Pathol. 57. 653–657. doi:https://doi.org/10.1177/0300985820943535.

Nicholls, J.M., Chan, M.C.W., Chan, W.Y., Wong, H.K., Poon, L.L.M., Tsao, S.W., Guan, Y., Peiris, J.M., 2020. Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat. Med. 13, 147–153. doi:https://doi.org/10.1038/nm.2278.

Parrish, C.R., Murcia, P.R., 2004. Infection and pathogenesis of canine, equine, and human influenza viruses in canine tracheas. J. Virol. 88, 9208–9219. doi:https://doi.org/10.1128/JVI.02034-14.

Parrish, C.R., Murcia, P.R., 2014. Infection and pathogenesis of canine, equine, and human influenza viruses in canine tracheas. J. Virol. 88, 9208–9219. doi:https://doi.org/10.1128/JVI.02034-14.
